Innovation1 Biotech Inc
Innovation1 Biotech Inc. focuses on researching, developing, producing, and selling pharmaceutical products. The company offers natural supplements for the treatment of symptoms associated with the flu and long covid under the NutraFlu and Nutravid19 brands; and other supplement and medical nutrition products. It also develops NLC001 that is in Phase II clinical trial for the treatment of long co… Read more
Innovation1 Biotech Inc (IVBT) - Total Liabilities
Latest total liabilities as of February 2024: $3.46 Million USD
Based on the latest financial reports, Innovation1 Biotech Inc (IVBT) has total liabilities worth $3.46 Million USD as of February 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Innovation1 Biotech Inc - Total Liabilities Trend (2018–2023)
This chart illustrates how Innovation1 Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Innovation1 Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Innovation1 Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aartech Solonics Limited
NSE:AARTECH
|
India | ₹119.06 Million |
|
Hempacco Co., Inc.
PINK:HPCO
|
USA | $18.82 Million |
|
Optima Medical Innovations Corp
PINK:TOKIF
|
USA | $3.35 Million |
|
TJIWI KIMIA
MU:OB9
|
Germany | €1.25 Billion |
Liability Composition Analysis (2018–2023)
This chart breaks down Innovation1 Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 28.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innovation1 Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innovation1 Biotech Inc (2018–2023)
The table below shows the annual total liabilities of Innovation1 Biotech Inc from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-08-31 | $3.51 Million | -91.47% |
| 2022-08-31 | $41.11 Million | +10007.77% |
| 2021-08-31 | $406.73K | -85.91% |
| 2020-08-31 | $2.89 Million | +1188.36% |
| 2019-08-31 | $224.05K | -67.38% |
| 2018-08-31 | $686.87K | -- |